Published 1 year ago • loading... • Updated 1 year ago

Biogen will stop selling its controversial Alzheimer’s drug Aduhelm

Biogen has announced that it will discontinue the sale and development of the Alzheimer's drug Aduhelm, refocusing efforts on their newly approved drug Leqembi.
The decision to drop Aduhelm is not due to safety or efficacy concerns, and the Swiss company Neurimmune will regain full rights to the medicine.
Biogen will redistribute resources from Aduhelm to other Alzheimer's treatments in their portfolio, such as BIIB080.

Insights by Ground AI

Does this summary seem wrong?

76 Articles

All

Left

Center

Right

Palestine Herald-Press

Biogen will stop selling its controversial Alzheimer’s drug Aduhelm

Biogen will stop selling its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster that stumbled after its launch a few years ago.

1 year ago

Read Full Article

Weatherford Democrat

Biogen will stop selling its controversial Alzheimer’s drug Aduhelm

Biogen will stop selling its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster that stumbled after its launch a few years ago.

1 year ago

Read Full Article

Fox Business

Biogen drops controversial Alzheimer's drug, focuses on other treatments

Biogen said it is discontinuing its controversial drug Aduhelm, so it can focus resources on other Alzheimer’s treatments that drive long-term growth.This includes shifting its priorities to its blockbuster drug Leqembi, which was developed with Japan's Eisai and approved in 2023."As a pioneer in Alzheimer’s disease, Biogen is reprioritizing resources to build a leading franchise to address the multiple pathologies of the disease and patient nee…

1 year ago·United States

Read Full Article

The Transylvania Times

Biogen will stop selling its controversial Alzheimer’s drug Aduhelm

Biogen will stop selling its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster that stumbled after its launch a few years ago.

1 year ago

Read Full Article

Valdosta Daily Times

Biogen will stop selling its controversial Alzheimer’s drug Aduhelm

Biogen will stop selling its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster that stumbled after its launch a few years ago.

1 year ago·Tifton, United States

Read Full Article

Bluefield Daily Telegraph

Biogen will stop selling its controversial Alzheimer's drug Aduhelm

(AP) — Biogen will stop selling its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster that stumbled after its launch a few years ago.

1 year ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year